Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant

Area of Science:

• Immunology
• Hematology
• Infectious Diseases

Background:

• Hematopoietic stem cell transplantation (HSCT) is a curative treatment for hematological conditions but leads to T-cell deficiency.
• Post-transplant infections are a major cause of morbidity and mortality, often involving multiple pathogens.

Purpose of the Study:

• To review the immune deficiency following HSCT.
• To discuss common post-HSCT infections.
• To explore the role of adoptive cellular therapy (ACT) in reconstituting T-cell immunity.

Main Methods:

• Review of literature on post-HSCT immune deficiency and infections.
• Analysis of studies on adoptive cellular therapy (ACT) using pathogen-specific T-cells.
• Examination of manufacturing advancements in ACT.

Main Results:

• ACT with donor or third-party pathogen-specific T-cells rapidly restores T-cell immunity.
• High efficacy (up to 90%) and low toxicity observed for CMV and EBV infections.
• Third-party T-cells show efficacy (up to 70%) in resistant CMV, EBV, and adenoviral infections.

Conclusions:

• ACT is a novel and effective strategy to combat infections in HSCT recipients.
• Advancements in ACT manufacturing enable broader application for multiple pathogens.
• Targeted T-cell therapies are crucial for improving HSCT outcomes.